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This study was prospectively designed to evaluate a phase II study of gefitinib for non-small-cell lung cancer (NSCLC) patients with
epidermal growth factor receptor (EGFR) mutations. Clinical samples were tested for EGFR mutations by peptide nucleic acid-locked
nucleic acid PCR clamp, and patients having EGFR mutations were given gefitinib 250mg daily as the second treatment after
chemotherapy. Poor PS patients omitted chemotherapy. Of 107 consecutive patients enrolled, samples from 100 patients were
informative, and EGFR mutations were observed in 38 patients. Gefitinib was given to 27 patients with EGFR mutations, and the
response rate was 78% (one complete response and 20 partial responses; 95% confidence interval: 58–93%). Median time to
progression and median survival time (MST) from gefitinib treatment were 9.4 and 15.4 months, respectively. Grade 3 hepatic toxicity
and skin toxicity were observed in one patient each. There were significant differences between EGFR mutations and wild-type
patients in response rates (78 vs 14%, P¼0.0017), and MST (15.4 vs 11.1 months, P¼0.0135). A Cox proportional hazards model
indicated that negative EGFR mutation was a secondary prognostic factor (hazards ratio: 2.259, P¼0.036). This research showed the
need for screening for EGFR mutations in NSCLC patients.
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Gefitinib is an orally active epidermal growth factor receptor
(EGFR) tyrosine kinase inhibitor that competes with ATP for the
ATP-binding site in the cytoplasmic tail of EGFR (Brehmer et al,
2005). Gefitinib was studied in two trials: the Iressa
s Dose
Evaluation in Advanced Lung Cancer (IDEAL)-1 and IDEAL-2
trials (Fukuoka et al, 2003; Kris et al, 2003). Patients enrolled in the
IDEAL-1 and IDEAL-2 trials were required to have failed only one
prior platinum-containing regimen, and a platinum plus docetaxel,
respectively. In the IDEAL trials, the response rates ranged from 9
to 19%. Grades 3 and 4 toxicities were relatively uncommon. Based
on the IDEAL trials, gefitinib received registration approval by the
US Food and Drug Administration (FDA) for the second- and
third-line treatment of non-small-cell lung cancer (NSCLC)
(Siegel-Lakhai et al, 2005). The Iressa
s Survival Evaluation in
Lung Cancer (ISEL) trial investigated gefitinib in second- and
third-line NSCLC patients to investigate the survival benefit of
gefitinib monotherapy compared with placebo. A total of 1692
patients who were refractory to or could not tolerate chemotherapy
were enrolled. The results showed significantly greater tumour
shrinkage in the gefitinib arm, but the overall survival durations
were similar in both arms: 5.6 months in treated patients vs 5.1
months in patients received placebo. This failure of gefitinib to
show a survival advantage over placebo resulted in controversy
about the registration (Thatcher et al, 2005; Twombly, 2005).
In 2004, it was shown that mutations in the EGFR gene are
significantly associated with response to two tyrosine kinase
inhibitors, gefitinib (Lynch et al, 2004; Paez et al, 2004). The
majority of EGFR tyrosine kinase domain mutations occur in two
‘hot spots’, exons 19 and 21. In exon 19, deletions eliminate four
highly conserved amino acids (LREA). In exon 21, a missense
point mutation substitutes an amino acid at position 858 (L858R).
Among various mutations found in the EGFR tyrosine kinase
domain, only the following have so far been positively associated
with a response to gefitinib or erlotinib from retrospective
analyses: G719C (exon 18), some of the common exon 19 deletions
(LREA), L861Q (exon 21) and L858R (exon 21) (Pao and Miller,
2005). All such mutations result in conformational changes that
lead to increased sensitivity to tyrosine kinase inhibitors.
Several retrospective studies have shown that higher rates of
these mutations were found in females, in never-smokers, in
Asians and in patients with adenocarcinomas (Mitsudomi et al,
2005; Tokumo et al, 2005). And a better response to gefitinib has
been reported in patients harbouring EGFR mutations (Taron et al,
2005). These results indicate that screening of patients for EGFR
tyrosine kinase domain mutations before treatment with gefitinib
or other EGFR inhibitors may predict the clinical benefit of the
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streatment. However, approaches frequently required biopsy or
surgical specimens, as well as skilful techniques (Lynch et al, 2004;
Paez et al, 2004; Mitsudomi et al, 2005; Pao and Miller, 2005;
Tokumo et al, 2005; Twombly, 2005). We developed a method,
peptide nucleic acid-locked nucleic acid (PNA-LNA) PCR clamp,
capable of detecting EGFR mutations in the presence of 100-fold
background levels of wild-type EGFR from normal cells (Nagai
et al, 2005). Because of its high sensitivity and specificity, PNA-
LNA PCR clamp was considered suitable to detect EGFR mutations
both in histological samples such as surgical specimens, and in
cytological samples such as sputum and pleural effusions.
This phase II study was prospectively designed to evaluate the
effect of gefitinib in NSCLC patients with EGFR gene mutations
screened by PNA-LNA PCR clamp.
PATIENTS AND METHODS
The two-step protocol of this phase II study, that is (i) testing for
EGFR mutations by PNA-LNA PCR clamp, and (ii) administering
gefitinib to NSCLC patients with EGFR mutations, were approved
by the Institutional Review Board (IRB) of Saitama Medical
University Hospital. This study was performed in accordance with
the Declaration of Helsinki (1964, amended in 2000) of the World
Medical Association.
Primary entry criteria and testing for EGFR mutations
Consecutive NSCLC patients who were admitted in our single
institution and gave written informed consent for testing for EGFR
gene mutations by PNA-LNA PCR clamp, which was designed to
detect 11 different EGFR mutations. Detection rate (sensitivity) by
PNA-LNA PCR clamp is 89% and its accuracy (specificity) is 100%.
In PNA-LNA PCR clamp, existence of other types of EGFR
mutation is realised by seeing escape of the inhibition of
amplification by the clamp primer, and, in this case, a direct
sequencing method is employed to seek other types of EGFR
mutation. Finally, overall sensitivity and specificity of this system
is 97 and 100%, respectively, using clinical samples (submitting).
The cytology specimens were divided into pathology samples (the
main sample) and PNA-LNA PCR clamp samples (a small aliquot).
When the pathologist confirmed a pathology sample to contain
cancer cells (i.e. rated as classes IV or V), the cells in the PNA-LNA
PCR clamp samples, which had been collected and stored in the AL
buffer (a buffer containing protein denaturant: Qiagen, Hilden
Germany), were then subjected to the analysis. While, the paraffin-
embedded tissue specimens were serially thin-sliced: one slice was
used to confirm the presence of cancer cells under microscopy,
whereas the others were investigated by the PNA-LNA PCR
reaction.
The PNA-LNA PCR clamp method has been described in detail
(Nagai et al, 2005). Briefly, primers used were
F18: 50-GGTAGCTGTTCAGTTAAAGAACACC-30 and
B18: 50-CCTTTGGTCTGTGAATTGGTC-30 for exon 18,
F19: 50-CTGGATGAAATGATCCACACG-30 and
B19: 50-TGGGTAGATGCCAGTAATTGC-30 for exon 19, and
F21: 50-CTGGATGGAGAAAAGTTAATGGTC-30 and
B21: 50-CAGCAAGTACCGTTCCCAAAG-30 for exon 21.
PCR primers were designed manually or by using Primer 3
software (http://frodo.wi.mit.edu/cgi-bin/primer3/primer3.cgi) so
that the Tm values were between 55 and 601C. Fluorogenic probes
containing LNA were manually designed and confirmed by the
LNA Tm prediction tool (http://lna-tm.com/) to have Tm values
between 54 and 561C. Peptide nucleic acid clamp primers, 14- to
18-mer in length, were designed according to the guidelines
(Ugozzoli et al, 2004). LNA-containing oligos were synthesised by
IDT (Coralville, IA, USA), and PNA oligos were synthesised by
Greiner Japan, Tokyo, Japan. For PNA-LNA PCR clamp, PCR
primers (200nM each), fluorogenic probes (100nM each) and a
PNA clamp primer (5mM) were added to the Basic Mixture
containing 25mM TAPS pH 9.3, 50mM KCl, 2mM MgCl2,1m M 2-
mercaptoethanol, 200mM each of dNTPs and 1.25U of Takara Ex
Taq HS (Takara Bio, Shiga, Japan). For PCR reactions, PCR and the
real-time amplification monitoring for the PNA-LNA PCR clamp
were performed using Smart Cycler II (Cepheid Sunnyvale, CA,
USA). PCR cycling was a 30-s hold at 951C followed by 45 cycles of
951C for 3s and 621C (exons 18 and 19) or 561C (exon 21) for 30s.
Secondary entry criteria and treatment schedule
After testing for EGFR mutations by PNA-LNA PCR clamp,
patients who satisfied the following inclusion criteria were
enrolled: (a) EGFR mutations, (b) inoperable stage III–IV and
recurrence after operation, (c) measurable region(s), (d) adequate
bone marrow (white blood cell countX4000mm
 3; platelet
countX100000mm
 3; hemoglobinX9.5gdl
 1), total bilirubin
p1.5mgdl
 1, transaminases less than twice the upper limit of
normal, and serum creatinine level p1.5mgdl
 1, (e) age 20 years,
(f) no medical problems severe enough to prevent compliance with
the study requirements, and (g) secondary informed consent to be
treated by gefitinib.
Gefitinib (250mg p.o. daily) was given as the second treatment
after disease was on progression by cytotoxic chemotherapy for PS
0–2 patients with EGFR mutations. In the case of poorer PS owing
to advanced disease, the first line chemotherapy was omitted and
gefitinib was administered as the first therapy. The other patients
not enrolled into the phase II study were clinically treated by
appropriate therapies according to our institutional manual, and
their data on EGFR mutation status and survival time were
collected and analysed.
Evaluation
Patients were evaluated by physical examination, chest X-ray, bone
scintiscan, computed tomography (CT) of the head, chest and
abdomen, and fiberoptic bronchoscopy, and clinical stages were
then determined according to the tumour-node-metastasis system.
Chest X-rays were assessed at least every 2 weeks after the initial
evaluation, and a chest CT was planned to evaluate tumour
response and tumour progression. Tumour response was classified
in accordance with Response Evaluation Criteria in Solid Tumours.
Before the first course, each patient was subjected to a complete
blood cell count (CBC), serum chemistry for renal and hepatic
functions, electrolyte analysis and urinalysis. CBC, serum chem-
istry, electrolyte analysis and urinalysis were assessed at least once
a week after the initial evaluation. The NCI Common Toxicity
Criteria (version 3) was used to grade organ system damage.
Statistical analysis
The primary end point of this study was the response to gefitinib
for patients with EGFR mutations. Sample size was determined to
be 25 patients with EGFR gene mutations. We chose a 75%
response rate as a desirable target level and a 50% response rate as
uninteresting. Our design had a power in excess of 90% and less
than 10% type I error. A total number of patients to be tested by
PNA-LNA PCR clamp was decided to be more than 100 patients
because about 30% of Japanese NSCLC patients were reported to
have EGFR mutations in previous articles (Mitsudomi et al, 2005;
Tokumo et al, 2005).
Secondary end points were survival, side effects and clinical
usefulness of PNA-LNA PCR clamp. Differences in response to
gefitinib and survival after gefitinib therapy between patients with
wild EGFR genes and those with mutant EGFR genes were assessed
to indicate a clinical usefulness of screening by PNA-LNA PCR
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sclamp. Furthermore, differences in overall survival from the initial
treatment between the groups, and whether EGFR mutations were
a prognostic factor were also investigated. Survival curves were
drawn using the Kaplan–Meier method, and Logrank was
calculated for evaluating survival differences between the groups.
A Cox proportional hazards model (multiple variate) using EGFR
mutations, sex, stage and PS was also employed using the data
from all the patients enrolled by the primary entry criteria. All the
analyses were calculated by SPSS
s 11.0J.
RESULTS
From September 2004 to October 2005, samples from 107 Japanese
NSCLC patients were tested by PNA-LNA PCR clamp but two
patients refused consent for checking for EGFR mutations
(Figure 1). One hundred patients (93%) of the 107 patients
provided adequate samples for evaluation of EGFR mutation
status, and samples from seven patients did not provide enough
DNA. PNA-LNA PCR clamp detected EGFR mutations in 38
patients (38%; 95% confidence interval (CI): 28–48%) who were 15
male and 23 female patients (Table 1). Their median age was 62
years old, and, of the 38 patients, 33 patients had adenocarcinoma.
Exon 19 deletions, L858R and L861Q were found in 25 (66%), 12
(32%) and 1 (2%) patients, respectively (Figure 1). On the other
hand, 62 patients (51 men/11 women; median age: 66 years;
adenocarcinoma: 43 patients) were judged to have wild-type EGFR.
There were significant differences between EGFR mutation-
positive and EGFR mutation-negative groups with regard to sex
(male vs female: P¼0.00001), histology (adenocarcinoma vs non-
adenocarcinoma: P¼0.02) and smoking (420 pack-years vs o20
pack-years: P¼0.003) (Table 1).
Phase II study
Of the 38 patients with EGFR mutations, gefitinib was given to 27
patients. The other 11 patients were not treated by gefitinib
because they did not meet the secondary entry criteria.
Four patients and 23 patients were given gefitinib as the first-
line and the second-line treatment, respectively. All of the 27
patients were assessed for response. One patient showed a
complete response (CR) and 20 patients showed partial responses
(PRs). The overall response rate was 78% (95% CI: 62–94%)
(Table 2). The response rate in the 23 patients treated by gefitinib
after chemotherapy was 74% (95% CI: 56–92%). When patients
were stratified by EGFR mutation types, response rates were 75%
(15 out of 20 patients) for exon 19 deletions, and 86% (six out of
seven patients) for L858R. There were no significant differences in
the response rates between the mutation types (w
2 test: P¼0.557).
For the 27 patients, median time to progression (TTP) from the
gefitinib treatment was 9.4 months. And median survival time
(MST) from the gefitinib treatment was 15.4 months (Figure 2).
 Consecutive 109 NSCLC patients from September 2004 to October 2005 in Saitama Medical University
107 patients
EGFR mutations: 38 patients 
Materials Patient no.
Sputum 3
Pleural
effusion
7
Needle 
aspiration 3
BF 
cytology 14
Histology 11
Type of mutation Patient no.
Exon 19 deletions 25 (66%)
L858R 12 (32%)
L861Q 1 (2%)  
2 patients refused testing EGFR mutations
Wild EGFR gene: 62 patients
Insufficient specimen 7 patients
Figure 1 Patients entered and source of specimen and type of EGFR mutation.
Gefitinib for NSCLC with EGFR mutations
A Sutani et al
1485
British Journal of Cancer (2006) 95(11), 1483–1489 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sThere were also no significant differences in survival time after the
gefitinib treatment between the patients with exon 19 deletions and
L858R (Kaplan–Meier, logrank: Po0.455). The 21 patients with
CR/PR had a longer TTP and overall survival (14.4þ and 19.1þ
months, respectively) than patients with stable disease/progression
(3.1 and 5.6 months, respectively).
All 27 eligible patients were assessable for toxicity (Table 3).
Grade 3 drug-related hepatic toxicity was observed in one patient
(4%), and Grade 3 skin toxicity occurred in one patient (4%).
Other gastrointestinal toxicities were mild and acceptable. No lung
toxicities were observed.
Clinical usefulness of PNA-LNA PCR clamp
To investigate the clinical usefulness of PNA-LNA PCR clamp
screening, patients with EGFR mutations detected by the test were
compared to those with wild EGFR. The response rates were
Table 1 Patients’ characteristics
Mutation Wild-type
(n¼38) (n¼62) P-value
Male/female 15/23 pts 51/11 pts 0.00001
Median age (years) (s.d., range) 62 (10.0, 44–79) 66 (12.0, 32–81) 0.09
Stage
I 1 pt (2.6%) 3 pts (4.8%) 0.175
II 1 pt (2.6%) 2 pts (3.2%)
III 9 pts (23.7%) 23 pts (37.1%)
IV 23 pts (60.5%) 22 pts (35.5%)
Relapse 4 pts (10.5%) 12 pts (19.4%)
Histology
Adenocarcinoma 33 pts (86.8%) 43 pts (69.4%) 0.02
Squamous cell carcinoma 2 pts (5.3%) 12 pts (19.4%)
Adenosquamous 1 pt (2.6%) 1 pt (1.6%)
Large cell carcinoma 0 pt (0.0%) 1 pt (1.6%)
Undifferentiated 2 pts (5.3%) 5 pts (8.1%)
Smoking
420 pack-years 13 pts (34.2%) 40 pts (64.5) 0.003
ECOG PS
0–2 34 pts (89.5%) 55 pts (88.7%) 0.906
3–4 4 pts (10.5%) 7 pts (11.3%)
Treatments
a
Operation 10 pts (26.3%) 23 pts (37.1%) 0.948
Chemotherapy 30 pts (78.9%) 43 pts (69.4%)
Irradiation 2 pts (5.3%) 6 pts (9.7%)
ECOG PS¼Eastern co-operative oncology group performance status; Pts¼patients.
aAll the treatments which were given to patients for the intervening periods of the
diseases.
Table 2 Efficacy of gefitinib in patients with EGFR mutation
CR PR s.d. PD Response
Prior chemotherapy (+) 1 16 5 1 17 pts/23 pts (74%)
(95% CI: 56–92%)
Prior chemotherapy ( ) 0 4 0 0 4 pts/4 pts (100%)
Exon 19 deletions 1 14 4 1 15 pts/20 pts (75%)
L858R 0 6 1 0 6 pts/7 pts (86%)
Total 1 20 5 1 21 pts/27 pts (78%)
(95% CI: 62–94%)
CI¼confidence interval; CR¼complete response; EGFR¼epidermal growth factor
receptor; PD¼progressive disease; PR¼partial response; Pts¼patients; s.d.¼
standard deviation.
EGFR 
mutation
Wild 
EGFR P-value
Response 78% 14% 0.0017
MST 15.4M 11.1M 0.0135
1.0
0.8
0.6
0.4
0.2
0
0 100 200 300
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400 500
EGFR mutantion(+): n=27
S
u
r
v
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Wild-type EGFR: n=7
600
Figure 2 Survival time curves after gefitinib treatment in patients with and without EGFR mutation are shown.
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ssignificantly different between patients with EGFR mutations
(78%) and patients with wild EGFR (14%) (w
2 test, P¼0.0017,
Figure 2). Median survival time after the gefitinib treatment was
significantly different between patients with EGFR mutations (15.4
months) and those with wild-type EGFR (11.1 months) (Kaplan–
Meier, logrank: P¼0.0135, Figure 2).
Furthermore, to clarify whether EGFR mutation status tested by
PNA-LNA PCR clamp could be a prognostic factor for NSCLC
patients, the relationship between EGFR mutation status and
overall survival were evaluated using 99 patients except for one
patient who was lost in follow-up. Figure 3 shows the comparison
of overall survival after the initial treatments between NSCLC
patients with EGFR mutations and those with wild-type EGFR by
the Kaplan–Meier method. Overall survival after the initial
treatment was significantly different between the groups (EGFR
mutations: 19.1 months and wild-type EGFR: 10.7 months, logrank:
Po0.0108). The Cox proportional hazards model (multiple
variate) was also applied using EGFR mutations, sex, stage and
PS. The latter three factors are well known as prognostic factors in
NSCLC patients (Brundage et al, 2002). The Cox proportional
hazards model indicated that detecting EGFR mutations was a
secondary prognostic factor (Table 4).
DISCUSSION
With PNA-LNA PCR clamp, we were able to determine EGFR
mutation status in a majority of the NSCLC patients using clinical
samples such as sputum and BF cytology. To determine EGFR
mutations, direct sequencing or PCR-single strand conformational
polymorphism methods are frequently employed (Lynch et al,
2004; Paez et al, 2004; Mitsudomi et al, 2005; Pao and Miller, 2005;
Tokumo et al, 2005; Twombly, 2005). However, these methods are
time-consuming and require specimens that consist mostly of
cancer cells. Another approach that analysis of an increased EGFR
gene copy number, based on fluorescence in situ hybridisation
analysis, could be used as a predictive marker for sensitivity to
gefitinib (Bell et al, 2005; Hirsch and Witta, 2005; Takano et al,
2005). However, this method also needs specimens consisting
mostly of cancer cells, significant operation time and skilful
technicians who have intertechnician variability. Thus, these
methods can be employed only at some academic medical centres.
The preferred and practical method is one that can sensitively,
specifically and quickly detect EGFR mutations from specimens
used for the diagnosis of lung cancers without removing
contaminating normal cells. Peptide nucleic acid-locked nucleic
acid PCR clamp can rapidly (within 2hours) detect EGFR
mutations from all specimens used to diagnose lung cancers, that
is, sputum, pleural effusion and bronchial washing which contain
many normal cells. This method is able to sensitively and
Table 3 Side effects of gefitinib in patients with EGFR mutation
No. of patients with CTC grade
(n¼27)
23 4
Haematologic toxicity
Neutropenia 1 0 0
Thrombocytopenia 0 0 0
Anaemia 0 0 0
Other toxicities
Diarrhoea 5 0 0
Nausea and vomiting 2 0 0
Acne/acneform 9 1 —
Abnormal liver function (AST, ALT) 1 1 0
Abnormal renal function 0 0 0
Acute lung injury 0 0 0
ALT¼alanine aminotransferase; AST¼aspartate aminotransferase; CTC¼common
toxicity criteria; EGFR¼epidermal growth factor receptor.
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Figure 3 Overall survival curves after the initial treatments in patients with and without EGFR mutation are shown.
Table 4 Cox proportional hazards analysis
Hazards ratio P-value
Mutation 2.259 0.036
Performance status 1.542 0.002
Male/female 1.053 0.887
Stage 1.029 0.319
A Cox proportional hazards model (multiple variate) using EGFR mutations, sex,
stage and PS was employed using the data from all the patients (n¼99*) enrolled by
the primary entry criteria. *Data missing: one patient.
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sspecifically detect all 11 types of EGFR mutations (Nagai et al,
2005) in the presence of 100-fold wild-type EGFR background
levels. These 11 mutations account for more than 95% of EGFR
mutations found (Lynch et al, 2004; Twombly, 2005).
PNA-LNA PCR clamp prospectively detected EGFR mutations in
38% (95% CI: 28–48%) of the consecutive patients with NSCLC.
Patients who were EGFR mutation-positive were mostly women
(61%) and had adenocarcinomas (87%), and significantly lower
smoking index (34%). These results were consistent with the
results of previous retrospective reports (Mitsudomi et al, 2005;
Tokumo et al, 2005). Some clinical studies are trying to select
patients to gefitinib treatment by clinicopathologic features of
adenocarcinoma and non-smoker without testing EGFR mutations.
Our data indicate such an approach is not feasible. For example,
when selecting patients with adenocarcinoma and smoking 420
pack-years, 15 of the 38 patients with EGFR mutations (39%)
would be missed, whereas 13 of the 62 patients without EGFR
mutations (21%) would be mistakenly included.
Furthermore, the presence of EGFR mutations detected by the
PNA-LNA PCR clamp was found to be a prognostic factor in
Japanese patients with NSCLC in this prospective screening. A Cox
proportional hazards model indicated that detecting EGFR
mutations was a significant prognostic factor and was superior
to sex or stage, indicating that incorporating the PNA-LNA PCR
clamp into clinical studies and clinical practice is critical.
This phase II study clearly showed the favourable response to
gefinitib in NSCLC patients with EGFR mutations. The response
rate was 78% and the lower limit of the 95% confidential interval of
response was 62%. In contrast to previous retrospective analyses
(Riely et al, 2006; Hirsch et al, 2006), patients with exon 19
deletions were equally responsive compared to those with L858R in
this study. This might be due to our small sample size, so these
data need to be confirmed in a larger trial. In EGFR mutation-
positive patients treated by gefitinib, TTP (9.4 months) of after the
gefitinib treatment and MST (19.1 months) after the initial
treatment were longer than in patients treated with the regimens
using platinum doublet. Detection of EGFR mutations clearly
differentiates gefinitib-sensitive patients from gefinitib-insensitive
patients with regard to response rate and survival times.
Four patients with EGFR mutations received gefitinib as the first
line treatment because they could not be given chemotherapy
owing to poor PS. Two patients had meningitis carcinomatosa.
One had multiple brain metastases. And one had repeated
aspiration pneumonia owing to recurrent nerve palsy. All of these
patients showed PR and obtained better PS. Their survival times
were 190, 183þ, 278þ and 296þ days, respectively, and all
returned home. This experience taught us the usefulness of testing
for EGFR mutations in patients with poor PS owing to advanced
disease. Thus, even in Europe and the US where frequencies of
EGFR mutations are low, incorporating testing for EGFR muta-
tions in clinical practice may provide a huge benefit to some
patients.
In conclusion, our study prospectively demonstrated the clinical
benefit of gefitinib given to NSCLC patients with good PS as the
second-line treatment harbouring EGFR mutations, and, also,
gefitinib given to NSCLC patients with poor PS as the first-line
treatment showed a favourable response. To attain this
benefit, screening clinical samples at the time of diagnosis is
imperative, and PNA-LNA PCR clamp is a good method to achieve
this aim.
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